HIV Seronegativity Clinical Trial
Official title:
CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study)
Verified date | September 2021 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
CCTG 603 is an open-label, two-arm, randomized (1:1) clinical demonstration project to determine if brief Motivational Interviewing (MI-B) added to a text-message based adherence intervention (iTAB) improves adherence to PrEP among transgender persons.
Status | Completed |
Enrollment | 263 |
Est. completion date | December 18, 2020 |
Est. primary completion date | September 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Transgender identity, defined as identifying differently from sex assigned at birth - Age 18 years or older - Risk of acquisition of HIV as evident by one or more of the following: Has at least one HIV infected sexual partner for =4 weeks OR, Anticipated or concern of unprotected anal or vaginal sex with a partner in the next 3 months OR, Any partner in the past 12 months AND at least one of the following: 1. any condomless anal or vaginal sex in the past 12 months 2. any STI diagnosed or reported in the past 12 months 3. exchange of money, gifts, shelter, or drugs for sex OR, PEP-use in the past 12 months - Negative for HIV infection by nucleic acid test (NAT) or other sensitive method such as 4th generation antigen/antibody test - Acceptable renal function as measured by calculated creatinine clearance of at least 60 mL/min by the Cockcroft-Gault formula (eCcr (male) in mL/min = [(140 - age in years) x (lean body weight in kg)] / (72 x serum creatinine in mg/dL) in the past 30 days Exclusion Criteria: - Unable to give informed consent - Active hepatitis B defined by a positive hepatitis B surface antigen (HBsAg) - Substantial medical condition that, in the opinion of the investigator, would preclude participation, as defined by - gastrointestinal condition that would impair absorption of study drugs - known condition of reduce bone density (e.g. osteoporosis or osteogenesis imperfect) that significantly elevate the risk of bone fracture - neurological or severe psychiatric condition that would significantly impair the ability to adhere to PrEP - tubular or glomerular kidney disease that could be exacerbated by tenofovir - other medical condition that would unacceptably increase the risk of harm from study drug or significantly impair the ability to adhere to PrEP - Suspected sensitivity or allergy to the study drug or any of its components - Currently using an essential product or medication that interacts with the study drug such as the following: - other antiretroviral agent (including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, integrase inhibitors, protease inhibitors or investigational antiretroviral agents) - if currently on TDF/FTC for PEP or PrEP they can switch to study provided drug but can not continue any other antiretroviral agent - agents with known nephrotoxic potential: - aminoglycoside antibiotics (including gentamicin) - IV amphotericin B - cidofovir - cisplatin - foscarnet - IV pentamidine - IV vancomycin - oral or IV gancyclovir - other agents with significant nephrotoxic potential - drugs that slow renal excretion - probenecid - immune system modulators - systemic chemotherapeutic agents (i.e. cancer treatment medications) - ongoing systemic corticosteroids (with the exception of short courses of tapering steroid doses for asthma or other self- limited condition). - interleukin-2 (IL-2) - interferon (alpha, beta, or gamma) - other agent known to have a significant interaction with TDF or FTC - Proteinuria 2+ or greater by urine dipstick - Pregnancy (if individual has a uterus) - Other condition that, in the opinion of the investigator, would put the participant at risk, complicate interpretation of study outcome data, or would otherwise interfere with participation or achieving the study objectives |
Country | Name | City | State |
---|---|---|---|
United States | Los Angeles Lesbian, Gay, Bisexual, and Transgender Center | Los Angeles | California |
United States | University of Southern California | Los Angeles | California |
United States | Family Health Centers of San Diego | San Diego | California |
United States | University of California, San Diego | San Diego | California |
United States | LA Biomed at Harbor-UCLA | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Diego | Family Health Centers of San Diego, Los Angeles LGBT Center, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, University of Southern California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PrEP Adherence | To compare adherence to fixed dose TDF/FTC, as measured by intracellular levels of TFV-DP > 1246 fmol/punch, between subjects randomized to receive iTAB with versus without brief Motivational Interviewing, when used for adherence support to pre-exposure prophylaxis among transgender individuals at elevated risk for HIV acquisition. | Baseline up to Week 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00065741 -
Botanical/Drug Interactions in HIV: Glucuronidation
|
Phase 1 | |
Completed |
NCT00056953 -
Peer Mentors for Adolescents in HIV Affected Families
|
Phase 2 | |
Completed |
NCT00047931 -
HIV-1 Vaccine Test in Uninfected Adult Volunteers
|
Phase 1 | |
Completed |
NCT03995862 -
Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region
|
||
Completed |
NCT00006327 -
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
|
Phase 3 | |
Completed |
NCT00076817 -
Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
|
Phase 1 | |
Completed |
NCT03191474 -
Linkage of Transgender Individuals to PrEP
|
N/A | |
Completed |
NCT00121121 -
Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers
|
Phase 1 | |
Completed |
NCT00009685 -
HIV-1 Vaccine Test in Uninfected Adult Volunteers
|
Phase 1 | |
Completed |
NCT00031304 -
Screening Protocol for HIV Vaccine Studies
|
||
Completed |
NCT00055237 -
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
|
Phase 2 | |
Completed |
NCT02125773 -
Pre-exposure Prophylaxis Accessibility Research and Evaluation 2
|
N/A | |
Terminated |
NCT00789789 -
Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
|
N/A | |
Completed |
NCT01761643 -
CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM
|
Phase 4 | |
Completed |
NCT01418235 -
Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT00028119 -
HIV Incidence and Participation Retention in Pune, India
|
||
Completed |
NCT00076232 -
A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
|
Phase 3 | |
Completed |
NCT00004579 -
A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
|
Phase 1 | |
Active, not recruiting |
NCT00013572 -
HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults
|
Phase 1 | |
Completed |
NCT00002231 -
Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
|
Phase 1 |